The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support the safe and appropriate use of the following medicines:
Valproate (Epilim) and Developmental Disorders: Update on ongoing EU review
Domperidone-containing medicines: reminder of the risk of cardiac adverse reactions-restricted indication, contraindications and reduced dose and duration of use
New CPD e-learning module on reporting suspected adverse drug reactions
Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter.
Download: hpra-drug-safety-newsletter-edition-81.pdf 242 KB